UAB: Altimmune’s Intranasal COVID Vaccine Candidate Shows Sterilizing Immunity in Preclinical Tests

Published on :

University of Alabama at Birmingham researchers report additional preclinical evidence of the potency of a single-dose, intranasal COVID-19 vaccine candidate – AdCOVID – that was created by Altimmune Inc., a Maryland-based clinical-stage biopharmaceutical company.